Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
aminolevulinic acid hydrochloride, Quantity: 1.5 g
Specialised Therapeutics Glio Pty Ltd
Aminolevulinic acid hydrochloride
Oral Liquid, powder for
Excipient Ingredients:
Oral
10 vials, 2 vials, 1 vial
(S4) Prescription Only Medicine
Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (GBM) on preoperative imaging, and who are intended for resection of the tumour.
Visual Identification: Gliolan is supplied as white to off white powder in a glass vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2013-11-07
GLI_CMI_AUNZ_ Change in AU sponsor Address_01May18_clean CORE CMI FOR GLIOLAN GLIOLAN ® _ _ _(Glio _ _–_ _lan or Glee _ _–_ _ o _ _–_ _lan or _ _Gl-io-lan) _ _Aminolevulinic acid _ _hydrochloride (ALA HCl)_ CONSUMER MEDICINE INFORMATION _Date of _ _Dispensing_ _Consumer Name_ _Pharmacist Name_ _Consumer Address_ _Pharmacist Address_ _Consumer Address_ _Pharmacist Address_ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Gliolan. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits . Your doctor has weighed the risks of you taking Gliolan against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET You may need to read it again. WHAT GLIOLAN IS USED FOR This medicine is used _ _ for the visualisation of certain brain tumours (called glioblastoma multiforme) during tumour surgery. Gliolan contains a substance called aminolevulinic acid hydrochloride (ALA HCl). ALA HCl accumulates preferably in tumour cells where it is transformed into another similar substance. If the tumour is then exposed to blue light this new substance emits a red-violet light, which helps the surgeon to better see what is normal tissue and what is tumour tissue. This helps the surgeon to remove the tumour while sparing healthy tissue. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. _This medicine is not addictive._ _This medicine is available only with _ _a doctor’s prescription._ _This medicine is not expected to _ _affect your ability to drive a car or _ _operate machinery._ _There is not enough information to _ _recommend the use of this medicine _ _for children under the age of 18 _ _years. _ BEFORE YOU TAKE IT _WHEN YOU MUST NOT TAKE IT_ DO NOT TAKE THIS MEDICINE IF YOU HAVE AN ALLERGY TO: - any medicine containing aminolevulinic acid hydrochloride or porphyrins ( Lugege kogu dokumenti
GLI_PI_AU_ SRR_6 July 2021 (clean) 1 Australian Product Information – GLIOLAN ® (aminolevulinic acid hydrochloride) Powder for Oral Solution 1 NAME OF THE MEDICINE aminolevulinic acid hydrochloride 30 mg/mL powder for oral solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 1.5 g of aminolevulinic acid hydrochloride (ALA HCl), equivalent to 1.17 g of aminolevulinic acid. One mL of reconstituted solution contains 30 mg of aminolevulinic acid hydrochloride (ALA HCl), equivalent to 23.4 mg of aminolevulinic acid. Excipient(s) with known effect For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM GLIOLAN is supplied in a vial as a powder for oral solution. The powder is a white to off-white cake. 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS GLIOLAN is indicated in adult patients for visualisation of malignant tissue during surgery for malignant gliomas that are glioblastoma multiforme (GBM) on preoperative imaging, and who are intended for resection of the tumour. 4.2 D OSE AND METHOD OF ADMINISTRATION GLIOLAN should only be used by experienced neurosurgeons conversant with surgery of malignant gliomas and in-depth knowledge of functional brain anatomy who have completed a training course in fluorescence-guided surgery. Dose The recommended dose is 20 mg aminolevulinic acid hydrochloride per kilogram body weight. Special Populations Elderly There are no special instructions for use in elderly patients with regular organ function. Renal or Hepatic Impairment No trials have been performed in patients with clinically relevant hepatic or renal impairment. Therefore, GLIOLAN should be used with caution in such patients. GLI_PI_AU_ SRR_6 July 2021 (clean) 2 Paediatric population The safety and efficacy of ALA in children and adolescents aged 0 to 18 years has not yet been established. No data are available. Method of administration The solution should be administered orally three hours (range 2-4 hours) before anaesthesia. Use of ALA under conditions other Lugege kogu dokumenti